Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review

Yamaguchi, Yuta; Maeda, Yukihide; Shibahara, Takayuki; Nameki, Shinichiro; Nakabayashi, Akihiko; Komuta, Kiyohide; Mizuno, Yumiko; Yagita, Mayu; Manabe, Yusuke; Morita, Takayoshi; Nishide, Masayuki; Watanabe, A.; Takamatsu, Hyota; Nishida, Sumiyuki; Hirano, Tôru; Shima, Yoshihito; Narazaki, Masashi; Kumanogoh, Atsushi

doi:10.1080/24725625.2020.1717747

Cited by 6 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have also reported on prolonged thrombocytopenia in patients with TAFRO syndrome ( 21 , 22 ). Yamaguchi et al also showed that the median recovery periods from prolonged thrombocytopenia in TAFRO syndrome patients were 25 and 50 days for patients treated with mono-therapy and combination therapy, respectively (defined as the time to increase the platelet count above 5×10 4 /μL) ( 22 ). In typical ITP, platelet counts recover to above 5×10 4 /μL in 1-2 weeks with glucocorticoid or IVIG treatment ( 23 - 25 ).…”

Section: Discussionmentioning

confidence: 85%

“…Previous studies have also reported on prolonged thrombocytopenia in patients with TAFRO syndrome (21,22). Yamaguchi et al also showed that the median recovery peri- RRT: renal replacement therapy, AKI: acute kidney injury, CKD: chronic kidney disease, Cre: creatinine ods from prolonged thrombocytopenia in TAFRO syndrome patients were 25 and 50 days for patients treated with mono-therapy and combination therapy, respectively (defined as the time to increase the platelet count above 5×10 4 / μL) (22). In typical ITP, platelet counts recover to above 5× 10 4 /μL in 1-2 weeks with glucocorticoid or IVIG treatment (23)(24)(25).…”

Section: Discussionmentioning

confidence: 88%

“…The median recovery periods for inflammation, renal dysfunction, and thrombocytopenia were 25 (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36), 37 , and 73 (41-135) days, respectively (Fig. 4c).…”

Section: Discussionmentioning

confidence: 99%

“…4c). Excluding Intern Med Advance Publication DOI: 10.2169/internalmedicine.1178-22 the patients with critical complications, the median recovery periods for inflammation, renal dysfunction, and thrombocytopenia were 20 (18)(19)(20)(21)(22)(23)(24)(25), 33 (20-39), and 44 (40-70) days, respectively (Fig. 4c).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review

et al. 2023

View full text Add to dashboard Cite

Finding the ideal balance between efficacy and safety of immunosuppression is challenging, particularly in cases of severe TAFRO syndrome. We herein report a 60-year-old man diagnosed with grade 5 TAFRO syndrome mimicking hepatorenal syndrome that was successfully treated by glucocorticoid, tocilizumab, and cyclosporin despite virus infection. Furthermore, by examining 14 peer-reviewed remission cases, we revealed that the recovery periods among inflammation, renal dysfunction, and thrombocytopenia were quite different, with recovery from thrombocytopenia notably slow. All patients requiring dialysis were successfully withdrawn from dialysis, and the reversibility from kidney injury was good. This clinical information will help clinicians plan treatments and tailor the intensity of immunosuppression.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition, the 1-year mortality rate of the remaining 21 cases who had received corticosteroids alone was 29%, and their median survival time was 4.5 months ( 4 ). Regarding second-line therapy, although the efficacy of cyclosporine A, tocilizumab, and rituximab as additional therapies and thrombopoietin receptor agonists for refractory thrombocytopenia have been reported, the treatment strategies using these agents have not been established ( 4 , 16 , 21 ). Kurose et al reported the relationship between histopathological findings and clinical parameters in cases of iMCD with or without TAFRO syndrome ( 19 ).…”

Section: Discussionmentioning

confidence: 99%

Acute Abdomen and Adrenal Swelling as the First Manifestations of TAFRO Syndrome

et al. 2023

View full text Add to dashboard Cite

TAFRO syndrome, a rare systemic inflammatory disorder, commonly develops in an acute or subacute manner, with an aggressive clinical behavior. A substantial number of cases of TAFRO syndrome presenting with abdominal pain, and adrenal abnormalities on imaging have also been reported. A 54-year-old man developed severe acute abdominal pain. Bilateral adrenal swelling was detected on computed tomography. Although the abdominal pain resolved spontaneously, a fever and anasarca were observed. The patient was eventually diagnosed with TAFRO syndrome, and corticosteroid administration resulted in remission. TAFRO syndrome should be included in the differential diagnosis of acute abdomen and adrenal abnormalities.

show abstract

TAFRO syndrome: A disease that known is half cured

Chen

Feng

Zhang

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

Thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome is rare in clinical practice. It is a systemic inflammatory disease caused by a cytokine storm. Its clinical manifestations include thrombocytopenia, systemic edema, fever, bone marrow fibrosis, renal insufficiency, and organ enlargement. The high mortality rate of TAFRO syndrome is due to the difficulty of acquiring biopsy samples for diagnosis and the rapid disease progression. This disease is poorly understood by clinicians. Early detection, accurate diagnosis, and timely treatment play key roles in prolonging the survival of the patients. This review summarizes the latest progress in the pathogenesis, diagnostic criteria, and treatment regimens of TAFRO syndrome, aiming to help clinicians better understand TAFRO syndrome and improve its diagnosis and treatment.

show abstract

Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review

Cited by 6 publications

References 37 publications

Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review

Severe TAFRO Syndrome Mimicking Hepatorenal Syndrome Successfully Treated with a Multidisciplinary Approach: A Case Report and Literature Review

Acute Abdomen and Adrenal Swelling as the First Manifestations of TAFRO Syndrome

TAFRO syndrome: A disease that known is half cured

Contact Info

Product

Resources

About